Novartis is a founding member of WIPO Re:Search, a consortium established to accelerate discovery and development of medicines, vaccines and diagnostics for neglected tropical diseases. Sponsored by the World Intellectual Property Organization (WIPO), the consortium includes pharmaceutical companies, leading research institutions and nongovernmental organizations.
Novartis and other member organizations will voluntarily provide intellectual property and expertise on a royalty-free basis to qualified researchers across the global health research community. Products developed using WIPO Re:Search data will be granted royalty-free licenses when distributed in least developed countries.
By providing a searchable public database of available intellectual property assets - information on individual compounds and associated data, screening hits from compound libraries and clinical trial data - the consortium aims to foster interactions with research organizations focusing on neglected tropical diseases, malaria, and tuberculosis.
“WIPO Re:Search is a groundbreaking example of how a multi-stakeholder coalition can put intellectual property to work for social benefit.”
Francis Gurry, WIPO Director General
WIPO is a United Nations agency with 184 member states, dedicated to development of a balanced and accessible intellectual property system that stimulates innovation and contributes to economic development while safeguarding the public interest.
As a founding member of the consortium WIPO Re:Search, Novartis voluntarily provides intellectual property and expertise under royalty-free licenses to qualified researchers worldwide focusing on neglected tropical diseases. The World Intellectual Property Organization (WIPO) sponsors the consortium, which includes pharmaceutical companies, leading research institutions and nongovernmental organizations.
Under the commitment to WIPO Re:Search, Novartis has contributed structures and screening data for more than 5 000 compounds tested in dose response and confirmed to inhibit growth of the malaria parasite by more than 50% at the highest screening concentration. In addition, data was provided for hundreds of compound structures targeting the mycobacterial respiratory functions and ATP (adenosine triphosphate) homeostasis and showing an effect on mycobacterial growth in a whole-cell screen. Novartis also agreed to discuss possible licensing arrangements for other intellectual property that users believe would be required to practice inventions development from information supplied by other consortium members.
Along with Novartis, pharmaceutical companies participating in the consortium include:
- Alnylam Pharmaceuticals
Major research institutions range from the US National Institutes of Health, South African Medical Research Council and the Swiss Tropical and Public Health Institute to Fundacao Oswaldo Cruz, Massachusetts Institute of Technology and the University of California, Berkeley.